Company: SWKH
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050155
Chunk: 12

Company: SWK Holdings Corp
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 12
---
 share data)

 Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Revenues:Finance receivable interest income, including fees$10,822 $9,498 $30,077 $30,519 Pharmaceutical development — 628 2,153 1,711 Other 60 292 536 395 Total revenues10,882 10,418 32,766 32,625 Costs and expenses:Provision (benefit) for credit losses(931)1,385 (1,635)10,777 Loss on impairment of intangibles assets209 — 209 5,771 Loss on disposal of inventory314 — 314 — Interest expense1,179 1,139 3,464 3,514 Pharmaceutical manufacturing, research and development expense147 585 1,550 1,635 Change in fair value of acquisition-related contingent consideration— — — (4,900)Depreciation and amortization expense2 234 40 1,169 General and administrative expense3,286 2,993 9,406 8,597 Income from operations6,676 4,082 19,418 6,062 Other income (expense), netUnrealized net gains on warrants2,640 47 2,563 178 Net gain on exercise and cancellation of warrants— — — 444 Loss on sale of assets— — (82)— Gain on sale of business1,601 — 1,601 — Net loss on marketable investments(246)(6)(314)(168)Realized gain on early payment of finance receivable— — 1,729 — Gain (loss) on revaluation of finance receivables— — (3,727)2,495 Realized and unrealized foreign currency transaction gains (losses)25 251 (113)775 Income before income tax expense10,696 4,374 21,075 9,786 Income tax expense1,916 906 4,220 2,170 Net income$8,780 $3,468 $16,855 $7,616 Net income per shareBasic$0.72 $0.28 $1.38 $0.61